NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether GoodRx and certain of its officers ...

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at online services stocks GoodRx Holdings Inc (NASDAQ:GDRX) and Bumble Inc (NASDAQ:BMBL). GoodRx stock is surging today, up 8.8% at $7.91 at last look, after an upgrade from Raymond James to "outperform" from "market perform," with a price-target hike to $16 from $14. This bull note follows the healthcare platform's inaugural investor day and prescription contracting agreement with supermarket chain Kroger (KR). Since the start of the y ...

文章核心观点 - 公司GoodRx运营一个药品价格比较平台,通过提供折扣码和优惠券帮助消费者获得较低的药品价格[4] - 公司主要收入来自与药品福利管理公司(PBM)的合作,PBM同意支付公司佣金[4] - 公司还有部分收入来自订阅计划,如Kroger Rx Savings Club[4] - 公司在IPO和后续期间一直强调与药店的良好关系是其业务计划的重要组成部分,但未告知投资者Kroger(占公司近25%处方交易收入)可能单方面拒绝接受公司折扣的重大风险[5] 根据相关目录分别进行总结 公司业务模式 - 公司运营药品价格比较平台,通过提供折扣码和优惠券帮助消费者获得较低的药品价格[4] - 公司主要收入来自与PBM的合作,PBM同意支付公司佣金[4] - 公司还有部分收入来自订阅计划,如Kroger Rx Savings Club[4] 公司披露的风险 - 公司在IPO和后续期间一直强调与药店的良好关系是其业务计划的重要组成部分,但未告知投资者Kroger(占公司近25%处方交易收入)可能单方面拒绝接受公司折扣的重大风险[5] - 2022年5月,公司披露一家连锁超市(后确认为Kroger)采取行动影响了大部分PBM折扣的接受,这可能导致公司第二季度收入损失约3000万美元[6][7] - 2022年11月,公司进一步披露Kroger问题对第三季度和第四季度的收入影响分别约4000万美元和4500万至5000万美元[8][9]

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09. While investors closely watch year-over-year changes in headline numbers -- revenue and ear ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Stephanie Davis - Barclays Daniel Grosslight - Citi Lisa Gill - JP Morgan Charles Rhyee - TD Cowen Stan Bernstein - Wells Fargo Securities Scott Schoenhaus - KeyBanc Sean Dodge - RBC Capital Markets John Ransom - RJF John Park ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 ________________________ ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise. Over the last four quarters, the company ...

Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue1 and Adjusted Revenue1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income1 of $32.6 million; Adjusted Net Income Margin1 ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9. The analyst in coverage cited the potential for strong subscriber growth, as well as a positive shift in the company's monthly active users (MAUs). GoodRx jumped nearly 4% premarket, but broad market headwinds are capping gains. The stock has support at its 80-day moving average, which has propped up ...

GoodRx Holdings, Inc. (GDRX) closed the last trading session at $6.77, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.74 indicates a 29.1% upside potential. The mean estimate comprises 17 short-term price targets with a standard deviation of $2.19. While the lowest estimate of $5 indicates a 26.1% decline from the current price level, the most optimistic analyst ex ...